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ABSTRACT
By in vivo DMS footprint and reporter gene analyses
we identified two transcription factor binding sites in
the human c-sisIPDGF B gene promoter. The low basal
activity of the PDGF B promoter in HeLa and undiffer-
entiated K562 cells, which express low PDGF B mRNA
levels, and in PC3 cells, which express a high PDGF B
mRNA level, results from binding of a weak transcrip-
tional activator between positions -84 and -61 relative
to the transcription start site. Cytotrophoblast-like
JEG-3 cells, which do not express the 3.5 kb PDGF B
mRNA, contain a transcriptional activator directed at
the -641-61 sequence, but DNA methylation may
render the endogenous promoter inaccessible to this
activator. A CCACCCAC element at position -61/-54
was identified as the in vivo binding site for a strong
transcriptional activator in phorbol ester-treated
megakaryocytic K562 cells, which express a high
PDGF B mRNA level. Primary human fibroblasts, which
do not transcribe the PDGF B gene, contain a trans-
criptional activator that recognizes an element be-
tween positions -60 and -45 but does not bind to the
endogenous unmethylated promoter. Our results
show that the complex expression pattern of the
human PDGF B gene involves the cell type-specific
expression of weak and strong transcriptional activa-
tors and regulation of promoter accessibility to these
factors.
INTRODUCTION
Platelet-derived growth factor (PDGF) is a collective term for the
three dimeric proteins that can be constituted out of type A and/or
type B polypeptide chains. The human PDGF A and B chain
precursors are encoded by two homologous genes located on
chromosomes 7 (1) and 22 (2,3), respectively. The B chain gene
is identical to the c-sis proto-oncogene (4-6). PDGF is a potent
growth factor and chemo-attractant for cultured cells of mesen-
chymal origin, such as fibroblasts (7,8) and smooth muscle cells
(9,10). Expression ofPDGF is tightly regulated in a cell type- and
developmental stage-specific manner and is thought to play a role
in wound healing and early development (reviewed in 11). PDGF
is synthesized in bone marrow megakaryocytes (12,13) and
stored within a-granules of platelets, from which it is released
during the clotting process (14). Other examples of cell types that
express PDGF are vascular endothelial (15) and smooth muscle
cells (16), placental cytotrophoblasts (17), macrophages (18) and
activated monocytes (19). Depending on the cell type, expression
of PDGF can be affected by very diverse extracellular stimuli,
such as transforming growth factor P (20), hypoxia (21) and shear
stress (22).
Via autocrine and/or paracrine pathways aberrant expression of
PDGF may play a role in the etiology of atherosclerosis, fibrosis and
certain types ofcancer (reviewed in 11). Whereas the PDGF A chain
has only weak transforming activity, over-expression of normal
PDGF B chains induces transformation of NIH 3T3 cells with high
efficiency (23-26). The long and GC-rich leader of the PDGF B
transcript can act as a potent translational inhibitor (27,28).
However, if tascription of the PDGF B gene is driven by a
sufficiently strong promoter, such as the SV40 early promoter/en-
hancer, the leader sequence does not prevent development of
fibrosarcomas in mice (29). Upon transfection of PDGF B cDNA
into NIH 3T3 cells the acquisition of features of transfonmation was
shown to correlate directly with the expression level of PDGF B
mRNA (30). Modulation of the transcription rate is an obvious
mechanism by which the expression level of the PDGF B chain
under normal and pathological conditions could be regulated.
Since localization of the transcription start site of the human
PDGF B gene (31), only little progress has been made in
understanding regulation of transcription of the gene. An attractive
model system in which to study regulation of the PDGF B
promoter is the human erythroleukemia cell line K562. Upon
treatment with the phorbol ester 12-O-tetradecanoylphorbol
13-acetate (TPA) K562 cells differentiate to megakaryocytes (32),
which is accompanied by a >200-fold increase in PDGF B mRNA
content (33). The induction of PDGF B mRNA is at the
transcriptional level (32) and is dependent on de novo protein
synthesis (33). In previous studies, DNA elements that may
regulate activity of the PDGF B gene promoter during TPA-
mediated differentiation of K562 cells were mapped by reporter
gene analyses and gel retardation assays (33,34). The first 72 bp
upstream of the transcription start site were found to be sufficient
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for minimal promoter activity in untreated. K562 cells (33).
Regions between positions -101 and -58 bp (33) and-64 and -39
bp (34) were reported to be essential for TPA inducibility of the
PDGF B promoter. In gel retardation assays, both regions were
shown to interact specifically with nuclear proteins from K562
cells and some complexes correlated with TPA-mediated
megakaryocytic differentiation (33,34). A recent reporter gene
analysis revealed that an AP-l-like sequence between -92 and -85
and an ETS-like sequence between -80 and -70 relative to the
major transcription start site are required for maximal activity of
the PDGF B promoter in cultured vascular endothelial cells. An
Spl-like sequence between -61 and -56 appeared to be required
for basal PDGF B promoter activity in endothelial cells and was
shown to interact with purified Spl in a DNase I footprint
experiment (35). Reporter gene analysis of the PDGF B promoter
in human osteosarcoma cell line U2-OS indicated that regions
between -244 and -203, -102 and -95 and -63 and -44 relative
to the transcription start site contain positive regulatory elements.
By gel retardation analysis the -63/1-44 sequence was shown to
interact in vitro with an Spi-like factor present in nuclear extracts
derived from U2-OS cells (36). In the studies that have been
described thus far, interactions between PDGF B promoter
sequences and nuclear proteins have always been examined by
reporter gene analysis and in vitro DNA binding experiments.
However, in living cells the PDGF B promoter is part of a specific
chromatin structure, which is not maintained in the in vitro
experiments. Therefore, DNA-protein interactions that were
mapped in vitro may not always reflect the interactions that actually
occur at the endogenous gene. We decided to try to map the actual
protein binding sites at the PDGF B promoter in a diverse panel of
human cell types by in vivo dimethyl sulfate (DMS) footprinting,
which has become more readily applicable by the development of
the ligation-mediated polymerase chain reaction (LMPCR) (37).
To complement the in vivo footprint results with functional data,
we also mapped transcription regulatory elements by reporter gene
analysis of the PDGF B promoter. The combined results enable us
to accurately map two transcription regulatory elements within the
PDGF B gene promoter that are recognized by activating
transcription factors in vivo in a cell type-specific manner.
Previous studies provided evidence for negative regulation of
the PDGF B promoter: in cultured dermal fibroblasts and
cytotrophoblast-like JEG-3 cells the PDGF B gene promoter is
active in a reporter gene assay, whereas these cells do not
detectably express the corresponding PDGF B transcript
(33,38,39). Recently, we showed that the PDGFB promoter is not
hypersensitive to DNase I in these cells and that nucleosome
phasing may play a negative transcription regulatory role in
fibroblasts. In addition, we mapped silencer elements within
intron 1 and downstream of the gene that may suppress activity
of the promoter in JEG-3 cells (39). To examine a potential role
forDNA methylation in regulating promoter activity we analyzed
the chromosomal methylation status at the PDGF B promoter by
genomic sequencing (40,41) and restriction enzyme analysis.
MATERIALS AND METHODS
Cell culture
Cell lines K562, JEG-3, HeLa and PC3 were all from the
American Type Culture Collection (Rockville, MD). Primary
human dermal fibroblasts (Hufi) were derived from fresh foreskin
biopsies, which were a kind gift of the Department of Surgery
(University Hospital, Nijmegen). Cells were grown in Dulbecco's
modified Eagle's medium supplemented with 10% fetal calf
serum and 125 U/ml streptomycin and 125 U/ml penicillin.
Megakaryocytic differentiation of K562 cells was induced by
addition of TPA (Sigma) to the culture medium (final concentra-
tion 2 ng/ml).
Reporter gene constructs
All recombinant DNA constructs were made according to standard
protocols (42). psis-112/+43CAT and psis-1758/ +43CAT have
been described earlier (39). psis-425/+43CAT was made by AvaI
digestion and subsequent recircularization of psis-1758/+43CAT.
Unidirectional deletion mutants of AvaI/SstI-linearized
psis-425/+43CAT (Fig. IA) were made with exonuclease Im
according to the technical manual of the Erase-a-Base System
(Promega): mutants that were to be tested in a reporter gene assay
were characterized by dideoxy sequence analysis (43).
psis-112/+18CAT was made by religation of the 130 bp PstI
fragment of psis-112/+43CAT into PstI-linearized psis-112/
+43CAT (this results in the deletion of an internal 28 bp PstI
fragment). psis-112/+18mutaCAT was made as follows. The 130
bp PstI fragment of psis-1 12/18CAT was cloned into the PstI site
of pGEM3-Zf(-) (Promega) and ssDNA was isolated. A 24 bp
oligonucleotide primer [5'-d(GAG GTG GGT GAT ATC AGC
CTT TCC)-31 was used for site-directed-mutagenesis according to
the Amersham protocol of the Oligonucleotide-Directed In Vitro
Mutagenesis System Version 2 (Amersham). Dideoxy sequence
analysis revealed that mutagenesis had resulted in a C-+A change
at position -63 and the insertion of an A residue between positions
-64 and -65 (data not shown). The mutated 130 bp PstI fragment
was recloned into the vector part of PstIdigested
psis-112/+43CAT. pSuperCAT is a promoterless chloramphenicol
acetyltransferase (CAT) gene vector. pCH110 (Pharmacia LKB)
contains the 0-galactosidase gene driven by the SV40 promoter.
Electropermeations and CAT assays
Supercoiled plasmid DNA was purified by CsCl gradient
centrifugation (42) and quantitated by means of both ethidium
bromide staining and spectrophotometric measurement. Cells
(3-5 x 107) were electropermeated with 10 ig pCH11O and 10
pmol CAT construct as previously described (39). All cells except
K562 were harvested 24-48 h after electropermeation. Immedi-
ately after electropermeation, K562 cells were divided equally
over two dishes. TPA was added to one dish and 24 h later both
undifferentiated and TPA-treated cells were harvested. Cell
lysates were prepared (42) and the protein content of each lysate
was determined in a protein assay (BioRad). Fixed amounts of
protein were tested for [-galactosidase activity (44) and,
subsequently, amounts of protein corresponding to equal 0-galac-
tosidase activity were assayed for CAT activity (45). First, pilot
assays were carried out to determine what time of incubation and
amount of protein derived from reference sample
psis-112/+43CAT would yield -20% conversion of [I4C]chlor-
amphenicol after subtraction of the background CAT activity of
pSuperCAT. These parameters were then used to determine the
relative CAT activities of all other constructs. Radioactive spots
were quantitated by measuring in a liquid scintillation counter,
from which the percentage acetylated chloramphenicol could be
determined. CAT values were corrected for background activity
by subtracting the mean values ofpSuperCAT.
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In vivo footprinting
Monolayers of PC3, HeLa and Hufi cells were cultured to
subconfluence on 15 cm dishes. The tissue culture medium was
replaced by medium containing 0.1% dimethyl sulfate (DMS).
After an incubation of 2 min at 37°C, the DMS-containing
medium was quickly aspirated and cells were washed four times
with phosphate-buffered saline (PBS) at 37°C. Cells were
harvested in lysis solution [300 mM NaCl, 50mM Tris-HCl, pH
8.0, 25 mM EDTA, 0.2% sodium dodecyl sulfate (SDS), 200
jg/ml proteinase K] at 1.5 ml/15 cm dish and incubated overnight
at 37°C. To induce megakaryocytic differentiation, K562 cells
were cultured in the presence of 2 ng/ml TPA for 5 days before
DMS treatment. Suspensions of untreated and TPA-treated K562
cells (3-5 x 105 cells/ml) were centrifuged (5 min, 500 g, room
temperature) and the cell pellet was resuspended in culture
medium at 5 x 107 cells/ml. DMS was added to 0.1% and after a
1 min incubation at 37°C, the DMS-containing medium was
diluted with 50 vol ice-cold PBS. Cells were quickly centrifuged
(5 min, 500 g, 4°C) and the cell pellet was washed three times
with ice-cold PBS. Cells were resuspended in lysis solution at 2
x 107 cells/ml and incubated overnight at 37°C.
Chromosomal DNA from all DMS-treated cells was further
purified by repeated extractions with phenol, chloroform and
diethyl ether. Subsequently, the DNA was precipitated with
ethanol and dissolved in 10mM Tris-HCl, pH 8.0, 1 mM EDTA
(TE). DMS methylation of control protein-free chromosomal
DNA and piperidine cleavage of in vivo and in vitro methylated
DNA at sites of modified guanine residues were performed
according toMaxam and Gilbert (46). Piperidine was removedby
lyophilization and the DNA dissolved in 0.3 M sodium acetate,
pH 7.0. The DNA was ethanol precipitated repeatedly and finally
dissolved in water. Trace amounts of piperidine were removed by
lyophilization and the DNA was redissolved in TE at 0.4 ig/ml.
Genomic footprinting was done by means of LMPCR as
described by Mueller and Wold (37) and modified by Garrity and
Wold (47). The PDGF B promoter-specific primers 1(s), 2(s) and
3(s), respectively [5'-d(CAT GGACTG AAG GGTTGC TC)-3',
5'-d(CTC TCA GAG ACC CCC TAA GCG CCC C)-3' and
5'-d(AGA CCC CCT AAG CGC CCC GCC CTG G)-3'] were
used for analysis of the lower strand. Primers 1(a), 2(a) and 3(a),
respectively [5'-d(CGC AAA GTA TCT CTA TCT AGG
GAA)-3', 5'-d(TAG GGA ATG AAA ATG GGC GCT GGC)-3'
and 5'-d(GGA ATG AAA AAT GGG CGC TGG CGG C)-3']
were used for the upper strand. For first strand synthesis, 2 jg
DMS/piperidine-treated DNA was annealed to primer 1(s/a) at
60°C. During the PCR amplification (18 cycles) annealing of
primer 2(s/a) was at 72°C. Annealing ofthe labeling primer 3(s/a)
was at 74°C. First strand synthesis, PCR amplifications and
labeling reactions were done using Thermococcus litoralis DNA
polymerase (Vent; New England Biolabs). Labeling reaction
mixtures were electrophoresed on 6% sequencing gels. Gels were
dried and exposed to X-ray film with two intensifying screens.
The footprinting data were quantified by scanning the autoradio-
grams with a densitometer (Kipp & Zonen, Delft, The Nether-
lands). Nucleotide sequence markers were generated by dideoxy
sequence analysis (43) of human c-sis subclone pAO121 (48).
DNA methylation analysis
Chromosomal DNA was isolated according to standard protocols
BamHl and subsequently with either MspI or HpaII. MspI and
HpaII digestions were monitored by adding small aliquots of the
digestion mixtures to undigested phage X DNA. Upon complete
digestion of the x DNA, the chromosomal DNA samples were
electrophoresed in a 1% agarose gel and transferred to a
Hybond-N+ filter (Amersham, UK). DNA was hybridized
overnight in 0.9 M NaCl, 50 mM sodium phosphate, 5 mM
EDTA, pH 7.7, 0.1% bovine serum albumin, 0.1% Ficoll, 0.1%
polyvinylpyrollidone, 0.5% SDS, 20 jg/ml herring sperm DNA
at 680C with 32P-labeled probe PR16 (39,49). Filters were
washed at 68°C in 18 mM NaCl, 1 mM sodium phosphate, 0.1
mM EDTA, pH 7.7, 0.1% SDS and then exposed to X-ray film
with two intensifying screens.
For genomic sequencing, chromosomal DNA was treated with
hydrazine in the presence of 1.5 M NaCl (46). Piperidine
cleavage, DNA purification and LMPCR were done as described
above for in vivo DMS footprinting. Nucleotide sequence
markers were generated by dideoxy sequence analysis (43) of
human c-sis subclone pAO121 (48).
RESULTS
Functional analysis of the human PDGF B promoter
reveals cell type-specific transcription regulatory elements
Earlier we showed that in a panel ofhuman cell lines (listed in Fig.
5) the activity of the first 112 bp upstream of the PDGF B
transcription start site does not differ significantly from the
activity of the first 1758 bp upstream of that site (39). To map the
transcription regulatory elements within the 112 bp region in
more detail, we prepared a set of unidirectional deletion mutants
fused to the CAT reporter gene (depicted in Fig. l A). The deletion
mutants were tested for promoter activity in the same panel of
human cell lines that differ in level ofPDGFB mRNA expression
(see also Fig. 5), namely untreated and TPA-treated (i.e.
megakaryocytic) K562 cells, Hufi, cytotrophoblast-like JEG-3
cells and carcinoma-derived HeLa and PC3 cells. Culturing of
K562 cells in the presence of TPA has already been shown to
result in 15-30-fold increased activity of the 112 bp fragment
after 24 h (Fig. 5; 39). Therefore, data for untreated and
TPA-treated K562 cells are presented in separate diagrams.
Figure lB shows that deletion up to position -64 does not
significantly lower promoter activity, except for a slight decrease
in JEG-3 cells. In TPA-treated K562 cells the 64 bp fragment
displays >4-fold increased activity compared with the 112 bp
fragment. Further deletion up to position -60 results in >5-fold
decreased activity in PC3, HeLa, JEG-3 and untreated K562 cells
compared with the activity of the 64 bp fragment, but does not
significantly affect activity in TPA-treated K562 cells and in
fibroblasts. Deletion up to position -44 leads to 10- and 3-fold
decreased promoter activity in TPA-treated K562 cells and
fibroblasts, respectively compared with the activity of the 60 bp
fragment. A 36 bp promoter fragment, which extends to 6 bp
upstream of the TATA box, displays near background activity in
all cell lines tested. The results suggest that sequences located
between positions -64 and -60 are required for activity of the
PDGF B promoter in PC3, HeLa, JEG-3 and untreated K562
cells, but not in fibroblasts and TPA-treated K562 cells. In these
last two cell types sequences located between positions -60 and
(42). Chromosomal DNA (-20 jig) was digested with EcoRI and -44 appear to be indispensable for promoter activity.
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Flgure 1. Reporter gene analysis of unidirectional deletion mutants of the human PDGF B gene promoter. (A) Schematic overview of PDGF B promoter deletion
mutants. Unidirectional deletion mutants were generated as described in Materials and Methods. Numbers indicate the positions ofPDGF B sequences relative to the
transcription start site. The transcription start site is marked by an arrow. (B) Relative CAT activities of lysates from cells electropermeated with the indicated PDGF
B gene promoter deletion mutants. Cells were electropermeated with a mixture ofpCHl 10 and a deletion mutant. Aliquots of lysate normalized to mean f-galactosidase
activity were tested for CAT activity. CAT activities were determined as percentage acetylated [14C]chloramphenicol/time. For background correction, mean CAT
activity of the promoterless construct pSuperCAT was subtracted from each value. For each cell type, the activity of psis-112/+43CAT was defined as 100%o. K562
cells cultured in the absence or presence ofTPA are presented as two separate cell types. Activities of deletion mutants are indicated as values relative to the activity
of psis-112/+43CAT. All data are means from four to six independent electropermeations. SD are indicated by effor bars.
To provide unequivocal proof for the cell type-specific activity
of the -64/-61 region site-directed mutagenesis was performed,
which resulted in aC-+A change at position -63 and the insertion
of an A residue between positions -64 and -65. The necessary
cloning steps inevitably resulted in deletion of a small down-
stream fragment located between positions +19 and +43 (see
Materials and Methods). Therefore, we also tested whether the
+191+43 region might affect reporter gene activity. As can be seen
in Table 1, the minor change in the -64/-61 region reduces
activity of the PDGF B promoter to background levels in
untreated K562 cells and PC3 cells and by >5-fold in JEG-3 cells.
However, it does not affect promoter activity in TPA-treated
K562 cells, which is in agreement with the deletion mutant
analysis. In addition, the results show that the +19/+43 region is
dispensable for activity of the PDGF B promoter. The combined
results from the reporter gene assays enable us to map two
transcription activating elements. The first element harbors (part
of) the -64/-61 region and is essential for promoter activity in
A
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B
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PC3, HeLa, untreated K562 and JEG-3 cells, whereas the second
element is located between positions -60 and -44 and is required
for promoter activity in TPA-treated K562 cells and fibroblasts.
Table 1. Effect of site-directed-mutagenesis on PDGF B promoter activity
Plasmid CAT activity (%)
K562 K562 + TPA PC3 JEG-3
-112/+43 169.3 ± 9.5 136.6 ± 23.9 122.1 ± 1.6 81.4 + 7.8
-112/+18 100±29.4 100±3.6 100± 13.6 100±2.3
-112/+18mut 0±0 90.7±1.8 0±0 13.9±2.9
See legend to Figure lB for details, except that CAT activity of
psis-1 12/+18CAT was defined as 100%. All data are presented as means ± SD
of two to four independent electropermeations. Only the PDGF B promoter
sequences present in the CAT constructs are indicated.
In vivo DMS footprinting reveals protein binding sites
in the human PDGF B promoter that co-map with the
transcription activating elements
Transient reporter gene assays are a powerful means to reveal the
presence of transcription factors and to map transcription
regulatory DNA elements. However, as the methylation status
and chromatin structure at the promoter in the reporter gene
construct may differ significantly from the situation at the
endogenous promoter, the assays may provide an artifactual view
of the promoter in situ. To study the PDGF B promoter directly
in the living cell, we performed in vivo DMS footprint analyses
in fibroblasts, untreated and TPA-treated K562 cells, HeLa cells
and PC3 cells according to the method of Mueller and Wold (37).
In HeLa, PC3 and both untreated and TPA-treated K562 cells
methylation at G-61 in the lower strand was increased by
2-3-fold compared with the naked DNA lane (Fig. 2A).
Enhanced methylation was sometimes observed at G-63 in PC3
and untreated K562 cells, but was never as pronounced as at
G-61. In the same strand methylation at G-1 was increased by
300% in PC3 and TPA-treated K562 cells and by nearly 200% in
HeLa cells. In addition, methylation of all G residues from
position -60 to -54 in the lower strand was decreased by almost
70% in TPA-treated K562 cells. In the upper strand, we detected
2-3-fold increased methylation at G-2 in PC3 and TPA-treated
K562 cells (Fig. 2B). The hypermethylation at G-61 in untreated
K562, HeLa and PC3 cells co-maps with the -64/-61 element that
was identified in the reporter gene assays. Similarly, the footprint
at'-61/-54 bp in TPA-treated K562 cells corresponds with the
-60/-45 element found in the reporter gene assays. No DMS
footprint was found in fibroblasts, suggesting that the PDGF B
promoter does not interact with transcription factors in vivo in
these cells. The enhanced methylation close to the transcription
start site in PC3, HeLa and TPA-treated K562 cells could not be
directly linked to a functional element and may result from the
binding of basal transcription factors.
DNA methylation may inhibit accessibility of the
human PDGF B promoter in JEG-3 cells, but not in
fibroblasts, HeLa and K562 cells
Fibroblasts and JEG-3 cells express transcriptional activators ofthe
PDGF B promoter, despite the absence of corresponding PDGF B
mRNA in these cells (33,38,39; this paper). To examine whether
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Figure 2. In vivo DMS footprint analysis of the human PDGF B gene promoter.
Open boxes indicate sites of hypomethylation and closed boxes sites of
hypermethylation. Numbers indicate the positions of the G residues relative to
the transcription start site. Nucleotide sequence markers were generated by
dideoxy sequence analysis of human c-sis subclone pAO121 (48). G residues
in the genomic footprint lanes correspond with the complementary C residues
in the nucleotide sequence ladders. (A) Lower strand; (B) upper strand.
DNA methylation could play a negative regulatory role in these
cells or in HeLa and untreated K562 cells, which express very low
levels of PDGF B mRNA, we analyzed the chromosomal
methylation status at the PDGF B promoter. Genomic sequencing
analysis reveals that the CpG dinucleotides at positions -20, -48,
-85 and -94 are heavily methylated in JEG-3 cells, whereas they
are unmethylated in fibroblasts and in untreated and TPA-treated
K562 cells (Fig. 3). These results are in full accordance with an
isoschizomer experiment focusing on the chromosomal methyla-
tion status ofa representative MspI site at position -85 ofthe PDGF
B promoter (Fig. 4A). Chromosomal DNA was pre-digested with
EcoRI and BamHI and subsequently with either MspI or its
methylation-sensitive isoschizomer HpaH. As can be seen in
Figure 4B, the MspI site at -85 is unmethylated in fibroblasts,
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Figure 3. Genomic sequence analysis ofCpG dinucleotides within the human
PDGF B gene promoter. Genomic DNA from the indicated cell types was
subjected to (unmethylated) C-specific DNA modification with hydrazine. The
modified DNA was broken by piperidine and the resulting fragments were
amplified by means ofLMPCR using primers I(s), 2(s) and 3(s). The genomic
sequence lanes show the C residues in the lower strand ofthe PDGFB promoter,
which correspond with the complementary G residues in the dideoxy sequence
ladders. CpG dinucleotides (indicated by open squares) are numbered after their
positions relative to the transcription start site. Nucleotide sequence ladders
were generated by dideoxy sequence analysis of c-sis subclone pAO121 (48).
HeLa and untreated K562 cells, as well as in PC3 and TPA-treated
K562 cells, which express high levels ofPDGF B mRNA. Only in
JEG-3 cells are most oftheMspI sites within the PDGFB promoter
and the 5'-part of exon 1 heavily methylated. In conclusion, these
results do not support a role for CpG methylation in regulating
activity ofthe PDGFB promoter in fibroblasts, HeLa and untreated
K562 cells. However, DNA methylation may inhibit activity ofthe
PDGF B promoter in JEG-3 cells.
DISCUSSION
By in vivo DMS footprint analyses and transient reporter gene
assays (summarized in Fig. 5) we have demonstrated that the first
64 bp upstream of the human c-sis/PDGF B gene transcription
start site contain two specific binding sites for transcriptional
activators. A transcriptional activator expressed in HeLa, PC3
and untreated K562 cells recognizes an element containing at
least part of the TCTC sequence at positions -64/-61. This is
supported by the observation that unidirectional deletion of the
-64/-61 region reduces promoter activity in a reporter gene assay
to near background levels in all three cell lines. In addition, a
site-directed mutation in the -64/-61 element abolishes promoter
activity in PC3 and untreated K562 cells. Finally, genomic
footprinting reveals enhanced methylation at G-61 in all three
cell lines, which indicates that the element is bound by a
trans-acting factor in vivo. As the activity of the PDGF B gene
Figure 4. Restriction enzyme analysis of the methylation status of the human
PDGF B gene promoter. (A) MspI restriction sites near the transcription start
site of the human PDGF B gene promoter (31). Numbers indicate the positions
(bp) relative to the transcription start site. M, MspI; E, EcoRI; P, Pvul; B,
BamHI. The open box indicates the location of genomic probe PR16 (39). The
MspI site at-85 bp relative to the transcription start site is marked by an asterisk.
(B) Southern blot analysis ofgenomicDNA (20 jg per lane) derived from HeLa
(1), K562 (2), K562+ 1 day TPA (3), K562+ 5 daysTPA (4), human fibroblasts
(5), PC3 (6) and JEG-3 (7). The DNA was pre-digested with EcoRI and BamHI
alone (-) or with EcoRI and BamHI and subsequently PvuII (P), HpaII (H) or
MspI (M). The DNA was hybridized with genomic probe PR16 (see also Fig.
4A).
promoter is 100-300-fold lower than that of the SV40 promoter/
enhancer in untreated K562, HeLa and PC3 cells (Fig. 5; 39), we
conclude that the factor that binds to the -64/-61 element is a
weak transcriptional activator. Although our previous results
showed that the high PDGF B mRNA level in PC3 cells
compared with HeLa cells probably results from a higher
transcription rate in PC3 cells (39), both cell types use the same
weak -64/-61 element for basal promoter activity. Presumably,
the promoter activity in PC3 cells is increased by an enhancer
element located downstream of the gene, while a silencer located
within intron 1 may down-regulate promoter activity in HeLa
cells (39,50). Despite contrary observations by others (32,33), we
reproducibly detected a low expression level ofPDGF B mRNA
in untreated K562 cells (39,50). A low percentage of untreated
K562 cells may differentiate spontaneously to megakaryocytes
(reviewed in 51), which could explain the expression ofPDGF B
mRNA. However, our reporter gene assays demonstrate that
activity of the PDGF B promoter in untreated K562 cells is
abolished by mutagenesis of the -64/-61 element, whereas
activity in TPA-treated megakaryocytic cells is not affected. In
addition, hypermethylation of G-61 would not be expected if
only a low percentage of untreated K562 cells had that site
occupied by a transcription factor. Thus, our current data indicate
that the PDGF B promoter is constitutively active in untreated
K562 cells due to binding of a weak transcriptional activator to
the -64/-61 element. The observation that the PDGF B promoter
is fully demethylated in untreated K562 cells is consistent with
this hypothesis. Whether the -64/-61 element interacts with a
known transcription factor is unclear, as a TCTC sequence or its
complement was not found as a specific binding site in a recent
compilation of transcription factors (52). PDGF B promoter
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Cell type 3.5 kb PDGF B Promoter Activating In vivo DMS CpG
mRNA activity element footprint methylation
HeLa + 0.39 ± 0.01 -64/-61 1,1 (G-1) no
PC3 +++ 0.31 ± 0.01 -64/-61 1,111 no
Hufi - 1.4 ± 0.07 -60/-45 - no
JEG-3 - 5.9 ± 0.14 -64/-61 N.D. yes
K562 + 0.95 0.3 -64/-61 I no
K562 + TPA +++++ 24.4 ± 6.3 -60/-45 I,II,1II no
Figure 5. Summary of structural and functional analysis of the human PDGF B gene promoter. The nucleotide sequence of the PDGF B promoter (31) is numbered
relative to the transcription start site. Sites of DNA-protein interactions that were mapped by in vivo DMS footprint analysis are boxed and indicated by Roman
numerals 1,1 and I; -, no detectable footprint; N.D., not determined. Activity ofthe -64/-61 (underlined) and the -60/-45 (double underlined) transcription activating
element in a transient reporter gene assay is indicated for each cell type. The TATA box is shown in bold. Expression levels of 3.5 kb PDGF B mRNA are summarized
from Northern blot analysis (39): -, undetectable; +, +++, +++++, increasing levels of expression. Activity of the PDGF B promoter (39) is indicated as the activity
of contruct psis-l 12/+43CAT relative to the activity of the SV40 promoter/enhancer construct pSV2CAT (00%o). The methylation status of the CpG dinucleotides
(m) was determined by restriction enzyme analysis (all cell types) and by genomic sequencing (all cell types except HeLa and PC3): no, unmethylated; yes, heavily
methylated.
fragments previously used in gel retardation assays with nuclear
extracts from K562 cells also contained the -64/-61 element,
suggesting that at least part of the in vitro DNA-protein
complexes result from interaction with the weak transcriptional
activator (33,34). JEG-3 cells, which do not contain the 3.5 kb
PDGF B mRNA, also express a transcriptional activator directed
at the -64/-61 element. Earlier we showed that the PDGF B
promoter is not hypersensitive to DNase I in JEG-3 cells (39),
suggesting that the transcriptional activator does not bind to the
endogenous promoter. We now show that the PDGF B promoter
and a large part of exon 1 is heavily methylated in JEG-3 cells,
which might cause inhibition of PDGF B promoter activity.
A second transcription activating element was localized by
deletion mutant analysis between positions -60 and -44 and
co-mapped with an in vivo DMS footprint extending from -61 to
-54 bp in TPA-treated K562 cells. TPA-mediated megakaryocy-
tic differentiation of K562 cells is accompanied by a >200-fold
increase in PDGF B mRNA level and a 10-30-fold increase in
activity of the PDGF B promoter in a reporter gene assay (Fig. 5;
33,39). In addition, the TPA-mediated increase in PDGF B
mRNA is dependent on de novo protein synthesis (33). Therefore,
we conclude that the increased activity of the PDGF B promoter
in TPA-treated K562 cells is the result of binding of a potent
transcriptional activator to the -60/-54 element. Enhancer
elements located downstream and far upstream of the PDGF B
gene may further increase the transcription rate in TPA-treated
K562 cells (39,50). Genomic footprinting revealed hyper-
methylation at G-61 in both untreated and TPA-treated K562
cells, which may result from binding of the same factor. This is
supported by previous observations that complexes between
PDGF B promoter fragments and nuclear proteins from either
untreated or TPA-treated K562 cells migrate at similar positions
in gel retardation assays (33,34). Our observation that mutagene-
sis or deletion of the -64/-61 element does not affect PDGF B
promoter activity in TPA-treated cells could be explained by
assuming that the weak activity of this element is obscured by the
potent transcription activating element located between -60 and
-45 bp. Alternatively, hypermethylation at G-61 may result from
binding of different factors in untreated and TPA-treated cells.
The footprint at -61/-54 in TPA-treated K562 cells closely
resembles an in vivo footprint at an identical sequence element
shown to be required for full promoter activity of the GATA-1
gene in mouse erythroleukemic MEL cells. The GATA-l gene
encodes an erythroid transcription factor that is specifically
expressed in erythroid precursors, mast cells and megakaryocytes
(53). In addition, the GATA-1 product itself may interact with
CACCC binding transcription factors (54). This raises the
interesting possibility that GATA-1 and PDGF B promoter
elements are regulated by related transcription factors. CACCC
element binding transcription factors were cloned from a murine
erythroleukemia cell line (55) and isolated from rat liver (56).
Recent in vitro binding studies indicated that the -61/-54 region
ofthePDGF B promoter interacts with purified Spi (35) and with
Sp 1-like proteins present in nuclear extracts from a human
osteosarcoma cell line (36). Whether known CACCC binding
transcription factors are involved in regulation of the PDGF B
promoter in megakaryocytic K562 cells remains to be deter-
mined.
Our present results indicate that primary dermal fibroblasts
express a transcriptional activator that recognizes DNA se-
quences between positions -60 and -45 bp of the PDGF B
promoter. Inhibition of PDGF B gene expression in fibroblasts
seems important, as over-expression of normal PDGF B chains in
fibroblasts may cause the development of fibrosarcomas via
autocrine stimulation of cell proliferation (11,23-26,29). Since
we could not detect transcription of the PDGFB gene in a nuclear
run-on assay (39) and the transcriptional activator does not
detectably bind to the endogenous promoter in vivo (this paper),
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the gene is probably repressed at the transcriptional level. This is
further supported by our previous observation that the PDGF B
promoter is not hypersensitive to DNase I in fibroblasts (39).
Thus far we have not found a transcriptional silencer within a
region stretching out from -12 to +25 kb relative to the
transcription start site of the PDGF B gene in fibroblasts (39,50).
Now that we show that the PDGF B promoter is unmethylated in
fibroblasts, a negative regulatory role for DNA methylation is
also unlikely. Possibly, a DNase I-hypersensitive site located
immediately downstream of the transcription start site in
fibroblasts (39) contains an element involved in specific nucleo-
some phasing, which may render the PDGF B promoter
inaccessible to trans-acting factors. A similar regulatory mechan-
ism was suggested to explain the observation that the cAMP-
responsive element (CRE) located upstream of the tyrosine
aminotransferase (TAT) gene is inaccessible to the CRE binding
protein (CREB) in certain cell lines that express nuclear CREB,
even after 5-azacytidine-mediated demethylation of CpG resi-
dues in the TAT CRE (57).
In conclusion, we provide direct in vivo evidence for cell
type-specific binding of a weak and a strong transcriptional
activator to the PDGF B gene promoter in a panel of human cell
lines. In addition, we have discussed the putative role of
chromatin structure in negative and positive regulation of the
gene. These studies illustrate the complexity of regulatory
mechanisms used by this gene to achieve its broad, but highly
specific, expression pattem.
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